2. Search Result
Search Result
Results for "

reducing sugars

" in MedChemExpress (MCE) Product Catalog:

56

Inhibitors & Agonists

4

Fluorescent Dye

7

Biochemical Assay Reagents

7

Peptides

16

Natural
Products

11

Isotope-Labeled Compounds

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0237
    Atractyloside A
    3 Publications Verification

    		 Others Cardiovascular Disease Others Cancer
    Atractyloside A possesses activities such as lowering blood pressure，reducing blood sugar，and anti-tumor effects.
    Atractyloside A
  • HY-N2024
    Maltose
    1 Publications Verification

    		 Endogenous Metabolite Metabolic Disease Cancer
    Maltose is a disaccharide formed from two units of glucose joined with an α(1→4) bond, a reducing sugar. Maltose monohydrate can be used as a energy source for bacteria.
    Maltose
  • HY-15916
    DTE
    2 Publications Verification

    Dithioerythritol; Cleland’s reagent

    		 Biochemical Assay Reagents Others
    DTE (Dithioerythritol) is a sulfur-containing sugar derived from the corresponding 4-carbon monosaccharide erythrose. DTE is an epimer of Dithiothreitol (DTT) (HY-15917). DTE is a thiol reducing agent .
    DTE
  • HY-109018A
    Velagliflozin proline
    1 Publications Verification

    		 SGLT Metabolic Disease
    Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .
    Velagliflozin proline
  • HY-N0640
    Kuromanin chloride
    5+ Cited Publications

    Chrysontemin; Cyanidin 3-O-glucoside chloride

    		 CD38 Neurological Disease Metabolic Disease
    Kuromanin chloride (Chrysontemin) is derived from mulberry leaves and has the effect of increasing blood sugar concentration and maintaining lipid metabolism balance to reduce obesity. Kuromanin chloride can inhibit CD38 enzymatic activities .
    Kuromanin chloride
  • HY-W073314
    2,2,2-Trifluoroethoxyamine hydrochloride

    O-(2,2,2-Trifluoroethyl)hydroxylamine hydrochloride

    		 Biochemical Assay Reagents Others
    2,2,2-Trifluoroethoxyamine (O-(2,2,2-Trifluoroethyl)hydroxylamine) hydrochloride can be used as an oxime reactant for coupling reactions with reducing sugars .
    2,2,2-Trifluoroethoxyamine hydrochloride
  • HY-D1619
    Cyanine3 hydrazide dichloride

    		Fluorescent Dye Others
    Cyanine3 hydrazide dichloride is a carbonyl reactive dye. Cyanine3 hydrazide dichloride allows the labelling of various carbonyl-containing molecules such as antibodies and other glycoproteins after oxidation by periodate, proteins or reducing sugars after oxidative stress or deamination .
    Cyanine3 hydrazide dichloride
  • HY-124281
    9(R)-PAHSA

    		NF-κB Akt Autophagy PI3K Others
    9(R)-PAHSA is a R-enantiomer of 9-PAHSA. 9-PAHSA is an orally available anti-inflammatory lipid that lowers blood sugar and reduces inflammation .
    9(R)-PAHSA
  • HY-124281A
    9(S)-PAHSA

    		Drug Isomer NF-κB Others
    9(S)-PAHSA is a S-enantiomer of 9-PAHSA. 9-PAHSA is an orally available anti-inflammatory lipid that lowers blood sugar and reduces inflammation .
    9(S)-PAHSA
  • HY-128530
    Tetrathiomolybdate

    TTM

    		 Cuproptosis Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Tetrathiomolybdate, an orally active anti-copper agent, reduces copper levels in the body. Tetrathiomolybdate has a protective effect on collagen-induced arthritis in mice. Tetrathiomolybdate also reduces blood sugar, but has no effect on mice with hereditary diabetes (db/db). Tetrathiomolybdate inhibit angiogenesis, also shows antiangiogenic effects in malignant pleural mesothelioma .
    Tetrathiomolybdate
  • HY-NP165
    Advanced glycation end products

    AGEs

    		 Biochemical Assay Reagents Metabolic Disease
    Advanced glycation end products (AGEs) is a series of stable compounds produced by non-enzymatic reactions of reducing sugars with proteins, lipids or nucleic acids. Advanced glycation end products is often used as a target for evaluating the inhibitory effects of anti-glycosylation compounds .
    Advanced glycation end products
  • HY-109018B
    Velagliflozin proline hydrate
    1 Publications Verification

    		 SGLT Metabolic Disease
    Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .
    Velagliflozin proline hydrate
  • HY-N2024R
    Maltose (Standard)

    		Reference Standards Endogenous Metabolite Metabolic Disease Cancer
    Maltose (Standard) is the analytical standard of Maltose. This product is intended for research and analytical applications. Maltose is a disaccharide formed from two units of glucose joined with an α(1→4) bond, a reducing sugar. Maltose monohydrate can be used as a energy source for bacteria.
    Maltose (Standard)
  • HY-B1245
    Salsalate
    2 Publications Verification

    Salicylsalicylic acid; Disalicylic acid

    		 Reactive Oxygen Species (ROS) Inflammation/Immunology Cancer
    Salsalate is a potent antirheumatic drug with oral activity that reduces irritation during gastric absorption and avoids direct inhibition of cyclooxygenase. Salsalate not only has significant anti-inflammatory effects, but also reduces blood sugar levels, improves insulin resistance, and reduces the expression of cytokines. Salsalate can protect mice from metabolic disorders caused by high-fat diet and effectively improve the symptoms of type 2 diabetes, atherosclerosis and non-alcoholic steatohepatitis [2 ] .
    Salsalate
  • HY-169566
    EGFR-IN-146

    		EGFR AMPK Metabolic Disease
    EGFR-IN-146 is an EGFR inhibitor that can inhibit the EGFR signaling pathway and improve insulin sensitivity by activating the AMPK pathway, which can effectively reduce blood sugar levels and body weight. EGFR-IN-146 has great potential in the study of diabetes and obesity .
    EGFR-IN-146
  • HY-113024R
    Pristanic acid (Standard)

    		Endogenous Metabolite Reference Standards Metabolic Disease
    D-Mannitol (Standard) is the analytical standard of D-Mannitol. This product is intended for research and analytical applications. D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β3-adrenergic receptor (β3-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells .
    Pristanic acid (Standard)
  • HY-N0640R
    Kuromanin chloride (Standard)

    Chrysontemin (Standard); Cyanidin 3-O-glucoside chloride (Standard)

    		 Reference Standards CD38 Neurological Disease Metabolic Disease
    Kuromanin (chloride) (Standard) is the analytical standard of Kuromanin (chloride). This product is intended for research and analytical applications. Kuromanin chloride (Chrysontemin) is derived from mulberry leaves and has the effect of increasing blood sugar concentration and maintaining lipid metabolism balance to reduce obesity. Kuromanin chloride can inhibit CD38 enzymatic activities .
    Kuromanin chloride (Standard)
  • HY-107567
    Carcinine

    β-Alanylhistamine

    		 Histamine Receptor Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Carcinine (β-Alanylhistamine) is a selective and orally active histamine H3 receptor antagonist with a Ki of 0.2939 μM. Carcinine can reduce histamine content. Carcinine exhibits anti-oxidant activity and neuroprotective effects. Carcinine shows positive inotropic effect and can reduce blood sugar and blood lipid levels. Carcinine can be used for the researches of inflammation, neurological, cardiovascular and metabolic disease, such as retinal damage, seizure and diabetes .
    Carcinine
  • HY-116956
    D-Erythrose

    		Biochemical Assay Reagents Others
    D-Erythrose is a four-carbon sugar classified as an aldose. D-Erythrose has unique chemical properties that make it an important intermediate in various metabolic pathways, especially in the biosynthesis of amino acids and nucleotides. It also plays a role in the pentose phosphate pathway, which generates reducing equivalents for biosynthetic reactions and cellular defense against oxidative damage.
    D-Erythrose
  • HY-170569
    Cetagliptin

    		Dipeptidyl Peptidase Cytochrome P450 P-glycoprotein Metabolic Disease
    Cetagliptin is an orally active inhibitor for dipeptidyl peptidase 4 (DPP-4) and CYP2D6 (IC50 of 6 µM). Cetagliptin is a substrate for P-glycoprotein. Cetagliptin reduces the GLP-1 degradation, maintains the level of postprandial blood sugar, and can be used in type 2 diabetes mellitus research .
    Cetagliptin
  • HY-W134326
    Polydextrose

    		Bacterial Infection Cardiovascular Disease Metabolic Disease
    Polydextrose is an orally active prebiotic. Polydextrose promotes the growth of Pediococcus pentosaceus ATCC 43200. Polydextrose reduces cholesterol and synergistically lowers blood sugar with Sitagliptin (HY-13749). Currently, it is mainly used in the research of diseases such as hyperlipidemia, type 2 diabetes, and postoperative iron deficiency anemia .
    Polydextrose
  • HY-N0378BGL
    D-Mannitol, M100 (GMP Like)

    Mannitol, M100 (GMP Like); Mannite, M100 (GMP Like)

    		 Endogenous Metabolite Apoptosis Adrenergic Receptor PGC-1α PKA Cardiovascular Disease Metabolic Disease Cancer
    D-Mannitol, M100 (GMP Like) (Mannitol, M100 (GMP Like)) is the GMP Like class D-Mannitol that can be used as pharmaceutical excipients. D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β3-adrenergic receptor (β3-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells .
    D-Mannitol, M100 (GMP Like)
  • HY-N0378AGL
    D-Mannitol, M200 (GMP Like)

    Mannitol, M200 (GMP Like); Mannite, M200 (GMP Like)

    		 Endogenous Metabolite Apoptosis Adrenergic Receptor PGC-1α PKA Cardiovascular Disease Metabolic Disease Cancer
    D-Mannitol, M200 (GMP Like) (Mannitol, M200 (GMP Like)) is the GMP Like class D-Mannitol that can be used as pharmaceutical excipients. D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β3-adrenergic receptor (β3-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells .
    D-Mannitol, M200 (GMP Like)
  • HY-N0378
    D-Mannitol
    10+ Cited Publications

    Mannitol; Mannite

    		 Endogenous Metabolite Apoptosis PGC-1α Adrenergic Receptor PKA Cardiovascular Disease Metabolic Disease Cancer
    D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β3-adrenergic receptor (β3-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells . D-Mannitol is commonly used to maintain osmotic pressure between the plant cytoplasm and the culture medium and protect cells when the cell wall is weakened or even removed .
    D-Mannitol
  • HY-107567B
    Carcinine dihydrochloride

    β-Alanylhistamine dihydrochloride

    		 Histamine Receptor Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Carcinine (β-Alanylhistamine) dihydrochloride is the dihydrochloride salt of Carcinine (HY-107567). Carcinine is a selective and orally active histamine H3 receptor antagonist with a Ki of 0.2939 μM. Carcinine can reduce histamine content. Carcinine exhibits anti-oxidant activity and neuroprotective effects. Carcinine shows positive inotropic effect and can reduce blood sugar and blood lipid levels. Carcinine can be used for the researches of inflammation, neurological, cardiovascular and metabolic disease, such as retinal damage, seizure and diabetes .
    Carcinine dihydrochloride
  • HY-170796
    α-Amylase-IN-11

    		Amylases Metabolic Disease
    α-Amylase-IN-11 (compound C5f) is an α-Amylase inhibitor (IC50=0.56 μM) that can reduce the sugar level in vivo. α-Amylase-IN-11 has a moderate inhibitory effect on α-glucosidase (α-glucosidase), with IC50=11.03 μM. α-Amylase-IN-11 can significantly reduce the glucose concentration in a mouse model and has the potential for use in diabetes research .
    α-Amylase-IN-11
  • HY-B1389
    Lactitol monohydrate

    D-Lactitol monohydrate

    		 Bacterial Others
    Lactitol monohydrate (D-Lactitol monohydrate) is a sugar analog of lactulose. Lactitol monohydrate acts as a prebiotic, fermented by intestinal flora, promoting the growth of beneficial bacteria (such as Lactobacillus and Bifidobacterium), inhibiting pathogenic bacteria, increasing volatile fatty acid production, and reducing ammonia levels. Lactitol monohydrate can be used as an alternative sweetener. Lactitol monohydrate can be also used in research on constipation and hepatic encephalopathy .
    Lactitol monohydrate
  • HY-204592
    idoBR1

    		TNF Receptor p38 MAPK Inflammation/Immunology
    idoBR1 is an orally active amino acid with an amino sugar. idoBR1 can significantly inhibit LPS (HY-D1056) induced TNF-α production and MAPK signaling pathway. idoBR1 can inhibit bacteria and human sialidase. idoBR1 can inhibit bacterial and human sialidase and reduce the binding of CD44 to hyaluronic acid (HA). idoBR1 can reduce the release of pro-inflammatory factors and promote the generation of anti-inflammatory factors. idoBR1 can be used for research on inflammatory conditions .
    idoBR1
  • HY-N0378S4
    D-Mannitol-d2

    Mannitol-d2; Mannite-d2

    		 Isotope-Labeled Compounds Endogenous Metabolite Apoptosis PGC-1α Adrenergic Receptor PKA Cardiovascular Disease Metabolic Disease Cancer
    D-Mannitol-d2 is the deuterium labeled D-Mannitol (HY-N0378). D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β3-adrenergic receptor (β3-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells . D-Mannitol is commonly used to maintain osmotic pressure between the plant cytoplasm and the culture medium and protect cells when the cell wall is weakened or even removed .
    D-Mannitol-d2
  • HY-N0378S2
    D-Mannitol-13C6

    Mannitol-13C6; Mannite-13C6

    		 Isotope-Labeled Compounds Endogenous Metabolite Apoptosis PGC-1α Adrenergic Receptor PKA Cardiovascular Disease Metabolic Disease Cancer
    D-Mannitol- 13C6 is the 13C labeled D-Mannitol (HY-N0378). D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β3-adrenergic receptor (β3-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells . D-Mannitol is commonly used to maintain osmotic pressure between the plant cytoplasm and the culture medium and protect cells when the cell wall is weakened or even removed .
    D-Mannitol-13C6
  • HY-N0378S1
    D-Mannitol-13C

    Mannitol-13C; Mannite-13C

    		 Isotope-Labeled Compounds Endogenous Metabolite Apoptosis PGC-1α Adrenergic Receptor PKA Cardiovascular Disease Metabolic Disease Cancer
    D-Mannitol- 13C is the 13C labeled D-Mannitol (HY-N0378). D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β3-adrenergic receptor (β3-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells . D-Mannitol is commonly used to maintain osmotic pressure between the plant cytoplasm and the culture medium and protect cells when the cell wall is weakened or even removed .
    D-Mannitol-13C
  • HY-N0378S
    D-Mannitol-d8

    Mannitol-d8; Mannite-d8

    		 Isotope-Labeled Compounds Endogenous Metabolite Apoptosis PGC-1α Adrenergic Receptor PKA Cardiovascular Disease Metabolic Disease Cancer
    D-Mannitol-d8 is the deuterium labeled D-Mannitol (HY-N0378). D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β3-adrenergic receptor (β3-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells . D-Mannitol is commonly used to maintain osmotic pressure between the plant cytoplasm and the culture medium and protect cells when the cell wall is weakened or even removed .
    D-Mannitol-d8
  • HY-N0378S5
    D-Mannitol-d1

    Mannitol-d1; Mannite-d1

    		 Isotope-Labeled Compounds Endogenous Metabolite Apoptosis PGC-1α Adrenergic Receptor PKA Cardiovascular Disease Metabolic Disease Cancer
    D-Mannitol-d is the deuterium labeled D-Mannitol (HY-N0378). D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β3-adrenergic receptor (β3-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells . D-Mannitol is commonly used to maintain osmotic pressure between the plant cytoplasm and the culture medium and protect cells when the cell wall is weakened or even removed .
    D-Mannitol-d1
  • HY-N0378S3
    D-Mannitol-2-13C

    Mannitol-2-13C; Mannite-2-13C

    		 Isotope-Labeled Compounds Endogenous Metabolite Apoptosis PGC-1α Adrenergic Receptor PKA Cardiovascular Disease Metabolic Disease Cancer
    D-Mannitol-2- 13C is the 13C labeled D-Mannitol (HY-N0378). D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β3-adrenergic receptor (β3-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells . D-Mannitol is commonly used to maintain osmotic pressure between the plant cytoplasm and the culture medium and protect cells when the cell wall is weakened or even removed .
    D-Mannitol-2-13C
  • HY-N0378R
    D-Mannitol (Standard)
    10+ Cited Publications

    Mannitol(Standard); Mannite (Standard)

    		 Reference Standards Endogenous Metabolite Apoptosis PGC-1α Adrenergic Receptor PKA Cardiovascular Disease Metabolic Disease Cancer
    D-Mannitol (Standard) is the analytical standard of D-Mannitol (HY-N0378). This product is intended for research and analytical applications. D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β3-adrenergic receptor (β3-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells . D-Mannitol is commonly used to maintain osmotic pressure between the plant cytoplasm and the culture medium and protect cells when the cell wall is weakened or even removed .
    D-Mannitol (Standard)
  • HY-N0378S6
    D-Mannitol-13C,d2

    Mannitol-13C,d2; Mannite-13C,d2

    		 Isotope-Labeled Compounds Endogenous Metabolite Apoptosis PGC-1α Adrenergic Receptor PKA Cardiovascular Disease Metabolic Disease Cancer
    D-Mannitol- 13C,d2 is the deuterium and 13C labeled D-Mannitol (HY-N0378). D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β3-adrenergic receptor (β3-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells . D-Mannitol is commonly used to maintain osmotic pressure between the plant cytoplasm and the culture medium and protect cells when the cell wall is weakened or even removed .
    D-Mannitol-13C,d2
  • HY-120657
    9-PAHSA

    		Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology
    9-PAHSA is an orally available anti-inflammatory lipid that lowers blood sugar and reduces inflammation. 9-PAHSA also improved carotid vascular calcification and attenuates cardiac hypertrophy and dysfunction in db/db mice. 9-PAHSA increases the viability of steatosis primary mouse hepatocytes (PMH). 9-PAHSA can be used in research on diabetes, inflammation, and cardiovascular disease .
    9-PAHSA
  • HY-N2468R
    Xylobiose (Standard)

    		TNF Receptor Claudin HSP Metabolic Disease Inflammation/Immunology
    Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) is an orally active Claudin 2/CLDN2 inhibitor and HSP27 inducer. Xylobiose works by regulating intestinal barrier function and glucose and lipid metabolism-related signaling pathways. Xylobiose inhibits CLDN2 expression to reduce intestinal permeability, induces HSP27 to enhance cell protection, and regulates the miR-122a/miR-33a axis to inhibit liver lipid synthesis and improve insulin resistance. Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. Xylobiose can be used in the study of type 2 diabetes and metabolic syndrome .
    Xylobiose (Standard)
  • HY-N2468
    Xylobiose

    1,4-β-D-Xylobiose; 1,4-D-Xylobiose

    		 TNF Receptor Claudin HSP Metabolic Disease Inflammation/Immunology
    Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) is an orally active Claudin 2/CLDN2 inhibitor and HSP27 inducer. Xylobiose works by regulating intestinal barrier function and glucose and lipid metabolism-related signaling pathways. Xylobiose inhibits CLDN2 expression to reduce intestinal permeability, induces HSP27 to enhance cell protection, and regulates the miR-122a/miR-33a axis to inhibit liver lipid synthesis and improve insulin resistance. Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. Xylobiose can be used in the study of type 2 diabetes and metabolic syndrome .
    Xylobiose
  • HY-N15201
    Betavulgarin

    		STAT Cancer
    Betavulgarin is an anticancer agent. Betavulgarin can be isolated from Sugar Beet (Beta vulgaris). Betavulgarin suppresses the proliferation, migration, colony formation, and mammosphere formation of breast cancer cells, and reduces the size of the CD44 +/CD24 − subpopulation and the expression of the self-renewal- related genes C-Myc, Nanog and Oct4. Betavulgarin promotes BCSCs death through the regulation of Stat3/Sox2 signaling .
    Betavulgarin
  • HY-114118
    Semaglutide
    20+ Cited Publications

    		 GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide
  • HY-114118B
    Semaglutide acetate
    20+ Cited Publications

    		 GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide acetate
  • HY-B1389R
    Lactitol monohydrate (Standard)

    D-Lactitol monohydrate (Standard)

    		 Reference Standards Bacterial Others
    Lactitol (monohydrate) (Standard) is the analytical standard of Lactitol monohydrate (HY-B1389). This product is intended for research and analytical applications. Lactitol monohydrate (D-Lactitol monohydrate) is a sugar analog of lactulose. Lactitol monohydrate acts as a prebiotic, fermented by intestinal flora, promoting the growth of beneficial bacteria (such as Lactobacillus and Bifidobacterium), inhibiting pathogenic bacteria, increasing volatile fatty acid production, and reducing ammonia levels. Lactitol monohydrate can be used as an alternative sweetener. Lactitol monohydrate can be also used in research on constipation and hepatic encephalopathy .
    Lactitol monohydrate (Standard)
  • HY-114118S
    Semaglutide-d8

    		Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide-d8 is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide-d8
  • HY-114118F
    Semaglutide, FITC labeled

    		GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide, FITC labeled is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide, FITC labeled promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide, FITC labeled also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide, FITC labeled has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide, FITC labeled can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide, FITC labeled
  • HY-114118S1
    Semaglutide-d8 tetraTFA

    		Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide-d8 tetraTFA
  • HY-114118A
    Semaglutide TFA
    20+ Cited Publications

    		 GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide TFA
  • HY-159944
    PPARγ agonist 14

    		PPAR Neurological Disease Metabolic Disease Inflammation/Immunology
    PPARγ agonist 14 (compound 3) is a PPARy agonist (EC50=2.4 μM) with anti-diabetic activity. PPARγ agonist 14 can improve intracellular glucose uptake, promote insulin release, and lower blood sugar. In addition, PPARγ agonist 14 also improves mitochondrial function, reduces oxidative stress, and inhibits inflammatory factors. PPARγ agonist 14 can be used in the study of neurodegenerative diseases, neuroinflammatory diseases, and other diseases .
    PPARγ agonist 14
  • HY-19904A
    (+/-)-Adomeglivant

    (+/-)-LY2409021

    		 Endogenous Metabolite Metabolic Disease
    (+/-)-Adomeglivant ((+/-)-LY2409021) is a potent and selective glucagon receptor antagonist with hypoglycemic activity. (+/-)-Adomeglivant is effective in lowering blood sugar levels in both healthy people and people with type 2 diabetes. (+/-)-Adomeglivant is well tolerated by glucagon signaling blockade in patients with type 2 diabetes and significantly reduces fasting and postprandial blood glucose with a concomitant reversible elevation of aminotransferases. Glucagon signaling inhibition by (+/-)-Adomeglivant is a promising potential inhibitory approach for patients with type 2 diabetes and warrants further evaluation of its benefits and risks in longer clinical trials .
    (+/-)-Adomeglivant
  • HY-W016715
    L-Cysteine hydrochloride hydrate
    5+ Cited Publications

    		 Endogenous Metabolite NF-κB Insulin Receptor Neurological Disease Metabolic Disease
    L-Cysteine hydrochloride hydrate is an orally active and essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine hydrochloride hydrate regulates CBS/H2S pathway, inhibits NF-κB activation and insulin and ghrelin secretion. L-Cysteine hydrochloride hydrate reduces blood sugar, vascular inflammation markers and appetite. L-Cysteine hydrochloride hydrate induces kidney damage. L-Cysteine hydrochloride hydrate can be used in the study of neurological diseases and diabetes .
    L-Cysteine hydrochloride hydrate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: